- Home
- ATNM vs CCEL Comparison
ATNM vs CCEL Comparison
Compare ATNM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- CCEL
- Stock Information
- Founded
- ATNM 2000
- CCEL 1989
- Country
- ATNM United States
- CCEL United States
- Employees
- ATNM N/A
- CCEL N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- ATNM Health Care
- CCEL Health Care
- Exchange
- ATNM Nasdaq
- CCEL Nasdaq
- Market Cap
- ATNM 46.5M
- CCEL 51.9M
- IPO Year
- ATNM N/A
- CCEL 1997
- Fundamental
- Price
- ATNM $1.21
- CCEL $5.82
- Analyst Decision
- ATNM Strong Buy
- CCEL Strong Buy
- Analyst Count
- ATNM 4
- CCEL 1
- Target Price
- ATNM $8.75
- CCEL $8.50
- AVG Volume (30 Days)
- ATNM 1.4M
- CCEL 11.7K
- Earning Date
- ATNM 04-29-2025
- CCEL 04-15-2025
- Dividend Yield
- ATNM N/A
- CCEL 4.27%
- EPS Growth
- ATNM N/A
- CCEL N/A
- EPS
- ATNM N/A
- CCEL 0.01
- Revenue
- ATNM N/A
- CCEL $32,102,750.00
- Revenue This Year
- ATNM N/A
- CCEL $2.21
- Revenue Next Year
- ATNM N/A
- CCEL $0.98
- P/E Ratio
- ATNM N/A
- CCEL $365.46
- Revenue Growth
- ATNM N/A
- CCEL 2.33
- 52 Week Low
- ATNM $1.03
- CCEL $4.96
- 52 Week High
- ATNM $10.24
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- ATNM 43.76
- CCEL 44.23
- Support Level
- ATNM $1.18
- CCEL $5.37
- Resistance Level
- ATNM $1.34
- CCEL $5.70
- Average True Range (ATR)
- ATNM 0.15
- CCEL 0.46
- MACD
- ATNM -0.03
- CCEL 0.03
- Stochastic Oscillator
- ATNM 11.99
- CCEL 50.89
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.